Treatment of ruptured intracranial aneurysms yesterday and now.

Objective: This prospective study is designed to detect changes in the treatment of ruptured intracranial aneurysms over a period of 17 years.

Methods: We compared 361 treated cases of aneurysm occlusion after subarachnoid hemorrhage from 1997 to 2003 with 281 cases from 2006 to 2014. Specialists of neuroradiology and vascular neurosurgery decided over the modality assignment.

Efficacy and Safety of Treatment of Ruptured Intracranial Aneurysms.

Objective: To compare the treatment results of ruptured aneurysms treated endovascularly with aneurysms treated with microsurgical clipping.

Methods: This prospective multicenter study recorded and analyzed 661 cases of ruptured intracranial aneurysms with consecutive subarachnoid hemorrhage treated between 1997 and 2014 at 2 large medical centers. Endovascular treatment was performed in 271 cases, and microsurgical treatment was performed in 390 cases.

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

Purpose: Prognosis of patients with glioblastoma is poor. Therefore, in glioblastoma patients, we analyzed whether antitumor vaccination with a virus-modified autologous tumor cell vaccine is feasible and safe. Also, we determined the influence on progression-free survival and overall survival and on vaccination-induced antitumor reactivity.

Treatment and long-term outcome of patients with orbital cavernomas.

Purpose: To evaluate the long-term prognosis of visual function in patients with orbital cavernomas after conservative and surgical treatment.

Design: Interventional case series.

Methods: The authors describe the outcome of 20 patients with cavernous hemangiomas of the orbit treated in their departments between 1988 and 2003.

Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels.

In tumour-induced angiogenesis of gliomas, vascular endothelial growth factor (VEGF) and its receptors fms-like tyrosine kinase (Flt-1) and kinase-insert-domain-containing receptor (KDR) play a major role and are promising targets for tumour therapy. Nevertheless, preliminary results of such therapies could not prove clinical efficacy and thus make a profound knowledge of VEGF regulation essential. Based on earlier results, which demonstrated an inhibitory influence of VEGF on Flt-1-expressing glioblastoma cells, in the present study we focused on the extent of VEGF and VEGF receptor coexpression and possible therapeutical consequences.

Radiation-induced cavernous hemangiomas of the brain: a late effect predominantly in children.

Introduction: The induction of cavernomas as a consequence of brain irradiation was first suspected in 1994 and has been controversial since that time.

Methods: Between 1986 and 2000, 189 cerebral cavernomas were diagnosed in the Neurosurgical Department of the University of Heidelberg; of those patients, 5 had received prior radiation therapy. The ages of these 5 patients were compared with those of the 184 others with naturally occuring cavernomas.

Cavernous hemangioma of the temporal muscle.

Intramuscular cavernous hemangiomas are often found in the brain, but they are uncommon in the muscles of the head and neck region, with the masseter being the most frequent, followed by the trapezius and sternocleidomastoideus. Such a lesion in the temporal muscle is an extremely unusual situation. A 55-year-old man presented with intermittent headaches and painless swelling of the right temple region brought on by stress and bending forward.

Cavernomas of the skull: review of the literature 1975-2000.

We describe four patients with intraosseous cavernous hemangiomas of the skull which were localized supraorbitally, parietally (two cases), and occipitally. The diameter ranged from 15 mm to 25 mm. They presented with slowly growing mass, tender to pressure, with spontaneous pain, and with freely mobile skin above the cavernoma sites.

Clinical impact and functional aspects of tenascin-C expression during glioma progression.

The extracellular matrix protein tenascin-C is expressed in processes like embryogenesis and wound healing and in neoplasia. Tenascin-C expression in gliomas has been described previously; however, the relation to clinical data remains inconsistent. Generally, analysis of tenascin-C function is difficult due to different alternatively spliced isoforms.